Isolation, Identification and Characterization of Degradation Impurity of Atorvastatin in Fixed Dose Combination of Atorvastatin and Ezetimibe

Desai, Rajesh; Koradiya, Suresh

dc.contributor.author	Desai, Rajesh
dc.contributor.author	Koradiya, Suresh
dc.date.accessioned	2024-11-17T06:57:27Z
dc.date.available	2024-11-17T06:57:27Z
dc.date.issued	2021-09-25
dc.identifier.citation	Desai, R., Koradiya, S. (2019). Isolation, Identification and Characterization of Degradation Impurity of Atorvastatin in Fixed Dose Combination of Atorvastatin and Ezetimibe. International Journal of Pharmaceutical Sciences and Drug Research, 11(5), 187-193.	en_US
dc.identifier.issn	0975-248X
dc.identifier.uri	http://10.9.150.37:8080/dspace//handle/atmiyauni/1595
dc.description.abstract	The objective of this study is to isolation and characterization of unknown degradation product of Atorvastatin calcium in combination formulation product with Ezetimibe by using modern techniques of separation and characterization. An unknown impurity is generating during a forced degradation study of Atorvastatin and Ezetimibe fixed-dose combination tablets. By using the gradient reversed-phase high-pressure liquid chromatographic method, unknown degradation impurity was detected and quantified in the range of 0.05% to 0.2% of Atorvastatin. The impurity was enriched by extreme oxidation degradation of Atorvastatin and isolated through preparative HPLC. The structure of the impurity was characterized by mass and NMR spectrum	en_US
dc.language.iso	en	en_US
dc.publisher	International Journal of Pharmaceutical Sciences and Drug Research	en_US
dc.relation.ispartofseries	;11(5), 187-193
dc.subject	Atorvastatin calcium	en_US
dc.subject	Ezetimibe	en_US
dc.subject	HPLC	en_US
dc.subject	Mass	en_US
dc.subject	NMR	en_US
dc.subject	Degradation	en_US
dc.title	Isolation, Identification and Characterization of Degradation Impurity of Atorvastatin in Fixed Dose Combination of Atorvastatin and Ezetimibe	en_US
dc.type	Article	en_US